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Abstract
Aim Irreversible electroporation (IRE) is a non-thermal
ablative option in patients unsuitable for standard thermal
ablation, due to its potential to preserve collagenous
structures (vessels and ducts) and a reduced susceptibility
to heat sink effects. In this series from two large tertiary
referral hepatobiliary centres, we aim to assess the safety/
outcomes of hepatic IRE.
Materials and Methods Bi-institutional retrospective, lon-
gitudinal follow-up series of IRE for primary hepatic
malignancy; [hepatocellular carcinoma (n = 20), cholan-
giocarcinoma (n = 3)] and secondary metastatic disease;
colorectal (n = 28), neuroendocrine (n = 1), pancreatic
(n = 1), breast (n = 1), gastrointestinal stromal tumour
(GIST, n = 1) and malignant thymoma (n = 1). Outcome
measures included procedural safety/effectiveness, time to
progression and time to death.
Results Between 2013 and 2017, 52 patients underwent
percutaneous IRE of 59 liver tumours in 53 sessions. All
tumours were deemed unsuitable for thermal ablation.
Cases were performed using ultrasound (US) or computed
tomography (CT) guidance. A complete ablation was
achieved in n = 44, (75%) of cases with an overall com-
plication rate of 17% (n = 9). Of the complete ablation
group, median time to progression was 8 months. At
12 months, 44% were progression-free (95% CI 30–66%).
The data suggest that larger lesion size ([ 2 cm) is asso-
ciated with shorter time to progression and there is highly
significant difference with faster time to progression in
mCRC compared with HCC. Median survival time was
38 months.
Conclusion This bi-institutional review is the largest UK
series of IRE and suggests this ablative technology can be a
useful tool, but appears to mainly induce local tumour
control rather than cure with HCC having better outcomes
than mCRC.
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Introduction
Percutaneous ablation is a treatment option for primary and
metastatic hepatic malignancy where surgical resection
cannot be performed. Heat-based ablative technologies
with radiofrequency (RFA) and microwave (MWA) energy
have a growing evidence base to support their safety and
effectiveness in the treatment of hepatic malignancy [1, 2].
For tumours located near thermosensitive structures (for
example; bile ducts or gallbladder), thermal ablation can
induce unwanted injury. Also, for tumour adjacent to large
hepatic blood vessels, thermal ablation can have reduced
efficacy due to heat sink effects [3]. Irreversible electro-
poration is a non-thermal ablative technique which can be
used in the aforementioned circumstances when thermal
ablative techniques may be unsafe or less effective. Unlike
thermal ablation which induces cell death through coagu-
lation necrosis, IRE primarily causes cell death through
apoptosis [4, 5]. This effect is achieved by placing elec-
trodes in/around a target tumour and applying high voltage
electrical currents to induce irreversible nanopore forma-
tion in cell membranes which alters cell permeability
ultimately leading to apoptosis [6]. A unique feature of IRE
is that it does not affect all tissues equally; tissues with
higher collagenous tissue content, for example, bile ducts
and blood vessels, lack a normal cellular membrane which
renders IRE’s ability to induce nanopore formation inef-
fective, thereby preserving these structures [5]. Therefore,
through IRE’s non-thermal mechanism which avoids heat
sink and its ability to reduce collateral damage, it has been
suggested as an alternative ablative technology in the liver
[6]. Pre-clinical studies in animals have confirmed IRE’s
ability to induce tumour necrosis while sparing adjacent
vulnerable structures and support its safety and effective-
ness [7–10]. IRE is commercially available for human
treatment as NanoKnife (AngioDynamics, New York,
USA). Limited clinical data exist in terms of IRE’s safety
and effectiveness in the treatment of hepatic malignancy.
The aim of this study is to contribute to the existing liter-
ature on local tumour control and complications with the
use of IRE in the treatment of both primary and secondary
hepatic malignancies (Fig. 1).
Materials and Methods
A retrospective analysis was performed to identify all
patients who had undergone percutaneous hepatic IRE at
two large hepatobiliary tertiary referral centres in the UK.
Patients and Tumour Characteristics
Between 2013 and 2017, a total of 59 tumours were treated
in 52 patients with primary or secondary hepatic malig-
nancy: 43 males and 9 females with a mean age of 64
(range 28–94). All cases were discussed at a multidisci-
plinary tumour board and were determined to be surgically
unresectable and in a location unsuitable for thermal
ablation (centrally located in proximity to major vascular
structures or adjacent organs). Exclusion criteria for IRE at
both institutions included: presence of a cardiac pace-
maker, uncontrolled cardiac arrhythmia, or uncor-
rectable coagulopathy (Fig. 2).
Tumour treated included primary hepatic malignancy;
hepatocellular carcinoma (n = 20), cholangiocarcinoma
(n = 3) and secondary metastatic disease; colorectal
(n = 28), neuroendocrine (n = 1), pancreatic (n = 1),
breast (n = 1), gastrointestinal stromal tumour (GIST,
n = 1) and malignant thymoma (n = 1). Mean tumour
diameter was 2.4 cm (range 0.7–5.2 cm) (Fig. 3).
Interventional Procedure
All cases were performed using the NanoKnife system in
accordance with the manufacturer’s guidance. General
anaesthetic with neuromuscular blockade (most commonly
Fig. 1 48-year-old male with colorectal liver metastases. Surveil-
lance PET-CT imaging detected recurrence adjacent to the resection
margin and either side of the left portal vein unsuitable for thermal
ablation
S. Mafeld et al: Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy…
123
using rocuronium bromide) is mandatory to minimise
unwanted muscular contraction.
IRE electrodes were percutaneously placed using image
guidance as per operator preference. A variety of imaging
modalities were employed, the most common being com-
puted tomography guidance (n = 35). Other modalities
included ultrasound alone (n = 13), contrast-enhanced
ultrasound (CEUS) in n = 8, CT/US fusion (n = 2) and
combined CT/US in (n = 1). Electrodes were placed in a
parallel direction with a distance of 1.0–2.0 cm apart. A
mean number of electrodes used were 3 (range 2–7) which
were sited in order to build an ablation zone encompassing
the target lesion and rim of surrounding tissue. Elec-
trode repositioning was carried out as required to enable
ablation of the whole lesion. Including initial test pulses, 90
pulses of 1500 v/cm were applied between each electrode
pair. Parameters were adjusted if necessary in order to
achieve a range of 20–50 Amperes, a level associated with
irreversible electroporation and cell death.
The pulses are delivered with ECG gating in the
refractory phase after myocardial depolarisation to min-
imise the risk of cardiac arrhythmias.
Post-intervention patients were transferred to the post-
anaesthesia care unit (PACU) for recovery and then
transferred back to the ward with a minimum of 6 h bed
rest. Mean hospital stay was 3 days (range 1–12).
Outcome Measures and Statistical Analysis
There were two outcome measures: time to progression and
time to death. As not all subjects progressed or died, these
were considered as survival outcomes. The outcome was
recorded as the time to the progression or death. Those
where these outcomes had not occurred were censored to
the last time where either progression or death was recor-
ded not to have occurred.
For patients with more than one lesion, progression was
deemed to have occurred, if one or more of the lesions
progressed. The time to the two outcomes was summarised
and displayed graphically using Kaplan–Meier methods.
Median survival was calculated, as was survival at specific
points in time. Corresponding confidence intervals were
calculated for the estimates at specific time points.
Patients were divided into three groups based on their
lesion size. For patients with more than one lesion, the
largest lesion size was considered. The logrank test was
used to compare time to progression and overall survival
between groups.
Patients were also divided into groups based on their
pathology. The majority of patients had either a CRLM or
HCC pathology, and specific comparisons of the outcomes
of these two groups only were made using the logrank test.
Patients with other pathologies were omitted from these
analyses.
Results
Adverse Events and Complications
In 53 IRE sessions, 9 (17%) complications occurred in 7
patients (Table 1) and are reported using the CIRSE
Quality Assurance Document and Standards for Classifi-
cation of Complications [11]. Half (n = 4) of these com-
plications occurred intra-procedurally with three instancesFig. 2 CT demonstrating parallel IRE electrode position for treat-
ment (third needle not shown).
Fig. 3 Post-treatment contrast-enhanced portal venous CT scan
demonstrates the ablation zone (arrow), surrounding a portal vein
branch (arrow head) which remains preserved and patent. The
remains alive 8 months post-procedure
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of atrial fibrillation and one subcapsular haematoma. The
remaining complications were identified post-operatively;
minor pain managed with analgesia (n = 2), peritonitis
(secondary to gallbladder perforation) and systemic
inflammatory response (SIRS) syndrome leading to death.
The death was observed 9 days post-IRE (mortality 1.8%)
in which a patient with pre-existing common bile duct
stones developed cholangitis, branch portal vein occlusion
and developed SIRS, but died despite intensive care
support.
Outcomes, Tumour Response and Survival
Technical success was defined as a complete response on
first follow-up imaging using either contrast-enhanced CT
or MRI at 4–8 weeks post-ablation. A complete ablation
was achieved in n = 44, (75%) of ablations in 37 patients.
All radiology images were reviewed by radiologists with
experience in post-ablation and hepatobiliary imaging. For
HCC, a complete response was reported according to
mRECSIST. An incomplete ablation was observed in
n = 13 cases (22%), one patient was lost to follow-up, and
1 patient died as outlined above. Where patients were
found to have an incomplete ablation, a second attempt at
IRE was not performed, and instead, patients were man-
aged by non-interventional treatments.
Of the complete ablation patient group, imaging follow-
up was planned to continue at three-monthly intervals after
the initial post-ablation imaging at 4–8 weeks. Median
time to progression was observed to be 8 months. At
12 months, the percentage that was progression-free was
44% (95% CI 26–62%) (Fig. 4).
Patients were divided into three categories based on
their lesion size. 9 patients (24%) had lesion of under
20 mm, 22 patients (59%) had a lesion of 20–30 mm,
whilst 6 patients (16%) had a lesion of over 30 mm. A
graphical illustration of the time to progression in the dif-
ferent groups is shown in Fig. 5. The logrank test was used
to compare the progression times in the three groups. The
results suggested evidence of a difference between groups
(p = 0.04) with larger lesion size associated with a shorter
time to progression.
Comparisons were also made between the two most
common pathologies: CRLM and HCC. The data suggested
that 17 patients (46% of all patients) were in the CRLM
category, whilst 11 were HCC patients (30%). The logrank
test suggested a highly significant difference in time to
progression in the two pathologies (p = 0.004). The
Kaplan–Meier plot (Fig. 6) shows that progression was
faster in the CRLM group than in HCC patients.
The second outcome examined was patient survival, the
time to death. The median survival time was found to be
38 months, with an inter-quartile range from 22 to
41 months. Patient survival at 12 months was 90% (95%
CI 72–97%), at 24 months was 65% (95% CI 40–81%) and
at 36 months was 52% (95% CI 22–75%). The Kaplan–
Meier plot (Fig. 7) demonstrates the survival times in the
patient group as a whole. While Fig. 8 is subdivided the
patients by lesion size and the logrank test suggested slight
evidence of a difference in overall survival between
groups, this difference was not statistically significant
(p = 0.06). These results are counter-intuitive, with the
longest survival in the group with the largest lesions, but
limited conclusions can be drawn from this due to small
sample size in this subgroup analysis.
Discussion
In patients with resectable hepatic malignancy, surgical
resection is regarded as the gold standard of care. However,
data from two of the most common hepatic cancers:
metastatic colorectal cancer (mCRC) and hepatocellular
carcinoma (HCC), suggest that less than 30% of patients
are typically suitable for surgery. Thermal ablation with
RFA and MWA has a proven role in the management of
unresectable hepatic malignancy [12, 13]. In small lesions,
ablation can rival surgical resection in terms of local
tumour control [12]. Ablation is also associated with a low
morbidity and mortality. In a meta-analysis of over 15,000
patients, the morbidity (major complication rate defined as
Table 1 All complications
during and after 53 IRE
procedures. Categorised by
CIRSE classification system
Classification (CIRSE) Event Number
1 Atrial fibrillation 3
Minor pain 2
2 0
3 Subcapsular haematoma 1
4 Gallbladder perforation with resultant bile leak and peritonitis 1
Systemic inflammatory response syndrome 1
5 0
6 Death 1
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any symptom that developed after ablation and persisted
for more than 1 week, or those that delayed hospital dis-
charge, threatened the patient’s life or led to substantial
morbidity and disability) was 4.1% for RFA and 4.6% for
MWA [14, 15]. Mortality was calculated at 0.15% for RFA
and 0.23% for MWA. Not all hepatic lesions are suit-
able for thermal ablation due to the danger of damaging
adjacent thermosensitive structures such as the gallbladder
and central bile ducts. Furthermore, ablation adjacent to
large vessels can be ineffective due to heat sink effects or
result in vessel thrombosis [16]. IRE is a comparatively
novel non-thermal ablation technology which can induce
tumour necrosis while sparing adjacent vulnerable struc-
tures. Emerging small data series support IRE’s safety and
effectiveness in the liver [7–10].
A recent systematic review has suggested a complica-
tion rate for hepatic IRE ranging from 11 to 36% [17]. The
data from our series are at the lower end of this rate at 17%.
However, these figures are considerably higher than
Fig. 4 A graphical illustration of the time to progression is shown in
the subsequent Kaplan–Meier plot. The plot is capped at 12 months,
as follow-up beyond this time occurred in only a smaller number of
patients
Fig. 5 A graphical illustration of the time to progression in the
different groups based on lesion size
Fig. 6 Highly significant difference in time to progression in the two
pathologies (p = 0.004)
Fig. 7 Kaplan–Meier survival curse for group as a whole
Fig. 8 Survival in the different subgroups subdivided by tumour size
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thermal ablation complication rates. This increase may be
related to the fact IRE requires a minimum of two elec-
trodes and ablations are more frequently adjacent to vital
hepatic structures. Of note, the cardiac arrhythmias appear
more frequent with IRE, while the vicinity of electrodes
close to the heart has been suggested as a possible cause,
but the precise mechanism is not fully understood. It has
also been shown that subclinical myocardial injury can
occur with IRE as evidenced by elevations in high-sensi-
tive troponin I [18]. Cardiac arrhythmias rarely impair
completion of an IRE procedure, as was the case in our
three instances of atrial fibrillation which were all either
self-limiting or medically managed [19]. Ablation of large
tumour volumes (40% of liver) has been shown in an
animal model to induce alterations in serum potassium
levels due to ionic shifts with nanopore formation resulting
in the potential for electrocardiogram arrhythmias, but this
mechanism is not felt to be applicable in this study as
lesional volume was considerably smaller [20].
A systematic review of mainly single-centre retrospec-
tive reviews has shown hepatic IRE to have a primary
efficacy of 67–100% [17]. Published data from multicentre
prospective trials in hepatic IRE are still awaited, but
preliminary presented results from (clinicaltrials.gov
ID:NCT01078415) for biopsy proven early-stage HCC
have indicated a 1-month complete response rate of 77%
[21]. Data from our study have indicated a 75% complete
response rate at the first follow-up imaging, which is within
the range of the aforementioned published studies. One
challenging factor which is rarely mentioned in the litera-
ture is the difficulty in interpretation of post-IRE imaging
which may impact on the primary efficacy outcomes.
Imaging appearances post-IRE remain at an investigative
stage; therefore, reported efficacy outcomes should be
interpreted with caution [22, 23]. Small histopathologic
studies have suggested that imaging responses to IRE may
be an inaccurate reflection of the ablation zone [24, 25].
This study and the literature as a whole on hepatic IRE
currently suggest that IRE is not as effective as its thermal
ablation counterparts, which are able to rival surgical
resection [26]. Caution should be observed in case selec-
tion with IRE as we have shown statistically significant
differences in outcomes with both size and pathology with
small (\ 2 cm) HCCs having the best outcomes in terms of
primary efficacy and longer-term tumour control. Other
studies have indicated tumour volume of [ 5 cm3 and
underlying disease type (HCC, cholangiocellular carci-
noma or metastatic disease) as independent risk factors
for early local recurrence [27].
The reasons for differences between IRE and thermal
ablation in terms of primary efficacy and local recurrence
are uncertain. The technical challenges of placing multiple
electrodes in parallel orientation into challenging hepatic
locations may be a factor, and a learning curve of at least
five cases has been suggested [28]. Traditional teaching
with thermal ablation suggests a 1-cm circumferential
ablation zone around a lesion to achieve recurrence-free
survival results rivalling surgery [26]. With IRE, electrodes
are typically placed at the periphery of a lesion with the
electroporation effect extending up to 5 mm beyond the
electrode position, and this means the margins achieved
using current IRE ablation protocols are not equivalent to
thermal ablation. Further investigation into optimum
ablation protocols beyond mathematical models is needed
[29].
The retrospective nature, relatively small sample size
and heterogeneous group of patients with varying
pathologies represent the largest limitation to this review.
Further heterogeneity exists with the imaging follow-up
protocol which employs both CT and MRI at varied time
points post-procedure. All patients were, however, planned
to have imaging follow-up at 4–8 weeks post-treatment. As
the current study was not designed as a trial, ultimately, the
information presented reflects ‘real-world data’ from two
large hepatobiliary centres. The nature of IRE is such that
only a limited patient cohort is suitable for this type of
ablation, and it therefore unlikely a gold standard ran-
domised control trial would be possible for this ablation
technology. The data obtained for the two largest groups:
HCC and CRLM add to the existing literature and should
therefore be of use in the process of clinical decision-
making. No definite conclusions can be drawn regarding
other metastatic malignancies.
Conclusion
This bi-institutional study represents the largest follow-up
series to date in the UK regarding hepatic IRE. Our data
suggest that lesion size \ 2 cm and HCC represent the
‘optimum’ case selection for IRE. However, even within
this group results do not equal the response rates published
for thermal ablation. IRE may therefore be an attractive
ablation option in patients with no other treatment option,
but interventional radiologists should remain aware of the
uncertainties regarding this technology.
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